Breast Cancer Research

official impact factor 5.79

Open Access Highly Access

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers

Mervi Jumppanen*, Sofia Gruvberger-Saal, Päivikki Kauraniemi, Minna Tanner, Pär-Ola Bendahl, Mikael Lundin, Morten Krogh, Pasi Kataja, Åke Borg, Mårten Fernö and Jorma Isola

Breast Cancer Research 2007, 9:R16 doi:10.1186/bcr1649

Accesses  

  • Last 30 days: 174 accesses
  • Last year: 1860 accesses
  • All time: 14276 accesses

Cited by

BioMed Central: 7 citations

Research article   Open Access Highly Accessed

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers

Eleonor Olsson, Gabriella Honeth, Pär-Ola Bendahl, Lao H Saal, Sofia Gruvberger-Saal, Markus Ringnér, Johan Vallon-Christersson, Göran Jönsson, Karolina Holm, Kristina Lövgren, Mårten Fernö, Dorthe Grabau, Åke Borg, Cecilia Hegardt BMC Cancer 2011, 11:418 (29 September 2011)

Research   Open Access

Does vimentin help to delineate the so-called 'basal type breast cancer'?

Renata U Kusinska, Radzislaw Kordek, Elzbieta Pluciennik, Andrzej K Bednarek, Janusz H Piekarski, Piotr Potemski Journal of Experimental & Clinical Cancer Research 2009, 28:118 (20 August 2009)

Research article   Open Access Highly Accessed

A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer

Andrew E Teschendorff, Carlos Caldas Breast Cancer Research 2008, 10:R73 (28 August 2008)

Research article   Open Access Highly Accessed

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

Gabriella Honeth, Pär-Ola Bendahl, Markus Ringnér, Lao H Saal, Sofia K Gruvberger-Saal, Kristina Lövgren, Dorthe Grabau, Mårten Fernö, Åke Borg, Cecilia Hegardt Breast Cancer Research 2008, 10:R53 (17 June 2008)

Basal-like and particularly BRCA1 hereditary breast cancer are associated with CD44+/CD24- cells, however tumorigenicity may not be confined to cells of this phenotype as they are found in very few HER2+ tumours.

Research article   Open Access Highly Accessed

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families

Hannaleena Eerola, Mira Heinonen, Päivi Heikkilä, Outi Kilpivaara, Anitta Tamminen, Kristiina Aittomäki, Carl Blomqvist, Ari Ristimäki, Heli Nevanlinna Breast Cancer Research 2008, 10:R17 (14 February 2008)

Letter   Free Highly Accessed

Are triple-negative tumours and basal-like breast cancer synonymous?

Emad A Rakha, David SP Tan, William D Foulkes, Ian O Ellis, Andrew Tutt, Torsten O Nielsen, Jorge S Reis-Filho Breast Cancer Research 2007, 9:404 (30 November 2007)

Research   Open Access Highly Accessed

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

Andrew E Teschendorff, Ahmad Miremadi, Sarah E Pinder, Ian O Ellis, Carlos Caldas Genome Biology 2007, 8:R157 (2 August 2007)

A feature selection method was used in an analysis of three major microarray expression datasets to identify molecular subclasses and prognostic markers in estrogen receptor-negative breast cancer, showing that it is a heterogeneous disease with at least four main subtypes.